Prognostic Value of CXCL12 in Non-Small Cell Lung Cancer Patients Undergoing Tumor Resection

Adjuvant chemotherapy is commonly indicated in lung cancer patients undergoing surgical therapy because tumor recurrence is frequent. A biomarker that can predict tumor recurrence in the postoperative period is currently unavailable. CXCR4 receptor and its ligand CXCL12 play important roles in metas...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceuticals (Basel, Switzerland) Switzerland), 2023-02, Vol.16 (2), p.255
Main Authors: Kogue, Yurie, Kobayashi, Hiroyasu, Nakamura, Yutaka, Takano, Takatsugu, Furuta, Chihiro, Kawano, Osamu, Yasuma, Taro, Nishimura, Tadashi, D'Alessandro-Gabazza, Corina N, Fujimoto, Hajime, Gabazza, Esteban C, Kobayashi, Tetsu, Fukai, Ichiro
Format: Article
Language:English
Subjects:
adjuvant chemotherapy
Adjuvant treatment
Analysis
Angiogenesis
Antibodies
Biomarkers
Cancer
Cell growth
Chemokines
Chemotherapy
Communication
CXCL12
CXCR4
Development and progression
Fibroblasts
Gene expression
Genetic aspects
Health aspects
Identification and classification
Immunohistochemistry
Lung cancer
Lung cancer, Non-small cell
Lung cancer, Small cell
Medical prognosis
Metastasis
Multivariate analysis
non-small cell lung cancer
Oncology, Experimental
Patients
Prognosis
surgical treatment
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adjuvant chemotherapy is commonly indicated in lung cancer patients undergoing surgical therapy because tumor recurrence is frequent. A biomarker that can predict tumor recurrence in the postoperative period is currently unavailable. CXCR4 receptor and its ligand CXCL12 play important roles in metastasis. This study investigated the value of tumor CXCL12 expression to predict prognosis and indicate adjuvant chemotherapy in non-small cell lung cancer patients. This study enrolled 82 non-small cell lung cancer patients. The expression of CXCL12 was evaluated by immunohistochemistry. The degree of CXCL12 expression was assessed using the Allred score system. Among all subjects, the progression-free survival and overall survival were significantly prolonged in cancer patients with low tumor expression of CXCL12 compared to patients with high tumor expression. Multivariate analysis showed that the increased level of CXCL12 is a significant predictor of progression-free survival and overall survival in NSCLC patients. Among subjects with high tumor CXCL12 expression, progression-free survival and overall survival were significantly improved in patients treated with adjuvant chemotherapy compared to untreated patients. These results suggest the potential value of tumor CXCL12 expression as a marker to predict prognosis and to indicate adjuvant chemotherapy after surgical tumor resection in non-small cell lung cancer patients.
ISSN:1424-8247
1424-8247
DOI:10.3390/ph16020255